Publications 2022

Eide IJZ, Nilssen Y, Lund-Iversen M, Brustugun OT (2022)
Factors affecting outcome in resected EGFR-mutated lung cancer
Acta Oncol, 61 (6), 749-756
DOI 10.1080/0284186X.2022.2066984, PubMed 35473448

Eide IJZ, Stensgaard S, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Sørensen BS, Brustugun OT (2022)
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Transl Lung Cancer Res, 11 (6), 953-963
DOI 10.21037/tlcr-21-995, PubMed 35832438

Kaźmierczak D, Eide IJZ, Gencheva R, Lai Y, Lewensohn R, Tsakonas G, Grundberg O, de Petris L, McGowan M, Brustugun OT, Ekman S, Hydbring P (2022)
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
Transl Lung Cancer Res, 11 (5), 722-734
DOI 10.21037/tlcr-21-955, PubMed 35693293

Publications 2021

Brustugun OT, Nilssen Y, Eide IJZ (2021)
Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study
Acta Oncol, 60 (10), 1250-1256
DOI 10.1080/0284186X.2021.1955971, PubMed 34313510

Eide IJZ, Brustugun OT (2021)
Lung cancer treated abroad with receptor tyrosine kinase inhibitor
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0147, PubMed 34505490

Eide IJZ, Brustugun OT (2021)
Lung cancer treated with receptor tyrosine kinase inhibits abroad
Tidsskr. Nor. Laegeforen., 141 (12), 1199-1201

Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, Hansen KH, Grønberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT (2021)
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Acta Oncol, 60 (12), 1565-1571
DOI 10.1080/0284186X.2021.1973092, PubMed 34486915

Publications 2020

Eide IJZ, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Brustugun OT (2020)
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Lung Cancer, 143, 27-35
DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138